PNC Financial Services Group
TARA icon

PNC Financial Services Group’s Protara Therapeutics TARA Stock Holding History

PNC Financial Services Group’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$447 Sell
117
-4
-3% -$19 ﹤0.01% 5007
2026
Q1 		$630 Sell
121
-1
-0.8% -$6 ﹤0.01% 4861
2025
Q4 		$650 Buy
122
+5
+4% +$28 ﹤0.01% 4784
2025
Q3 		$509 Buy
+117
New +$379 ﹤0.01% 4799

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

PNC Financial Services Group's TARA Position: Q2 2026 in Review

PNC Financial Services Group reduced its Protara Therapeutics (TARA) stake by 3.3% in Q2 2026, selling an estimated $19 and leaving 117 shares worth $447. The position accounts for ﹤0.01% of the portfolio, ranked #5007.

PNC Financial Services Group first reported a position in TARA in Q3 2025 and has held it in 4 quarters since. The position peaked at $650 in Q4 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • PNC Financial Services Group held 117 shares of Protara Therapeutics worth $447 as of Q2 2026.
  • PNC Financial Services Group sold 4 Protara Therapeutics shares in Q2 2026, an estimated $19.
  • Protara Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #5007 holding.
  • PNC Financial Services Group first reported a position in Protara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • PNC Financial Services Group's Protara Therapeutics position peaked at $650 in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.